Everolimus As an MTOR Inhibitor Suppresses Endometriotic Implants: an Experimental Rat Study

Overview

Journal Geburtshilfe Frauenheilkd

Specialty Gynecology & Obstetrics

Date 2017 Feb 14

PMID 28190891

Citations 14

Authors

T Kacan

C Yildiz

S Baloglu Kacan

M Seker

H Ozer

A Cetin

Affiliations

Soon will be listed here.

Abstract

Mammalian target of rapamycin is a pathway to block apoptosis. Recent studies showed that the activity of mammalian target of rapamycin pathway increases in endometriotic lesions. Aim of the present study was to study the effect of everolimus agent, a rapamycin analog, in an experimental endometriosis model. Endometriosis established by the autotransplantation of uterine tissue in the peritoneal cavity was confirmed in 24 rats. The animals were then randomly divided into three groups to receive either everolimus (1.5 mg/kg/day, p. o.), anastrozole (0.004 mg/day, p. o.), or normal saline (0.1 mL, i. p.) for 14 days. Endometriotic foci were excised, stained with hematoxylin and eosin, and endometriosis was scored semiquantitatively. In addition, immunohistochemical examination were performed using primary antibodies of vascular endothelial growth factor, CD117, and Bax. Both anastrozole and everolimus lowered endometriosis scores. Significant decreases in ovarian follicles were observed following anastrozole treatment but not everolimus treatment. Through its apoptosis-promoting effect, everolimus suppressed endometriotic foci without negatively affecting ovarian reserve. These findings support the hypothesis that everolimus merits further study on the way to developing a new endometriosis drug.

Citing Articles

mTOR inhibitors as potential therapeutics for endometriosis: a narrative review.

Nakamura A, Tanaka Y, Amano T, Takebayashi A, Takahashi A, Hanada T Mol Hum Reprod. 2024; 30(12).

PMID: 39579091 PMC: 11634386. DOI: 10.1093/molehr/gaae041.

The "Road" to Malignant Transformation from Endometriosis to Endometriosis-Associated Ovarian Cancers (EAOCs): An mTOR-Centred Review.

Hablase R, Kyrou I, Randeva H, Karteris E, Chatterjee J Cancers (Basel). 2024; 16(11).

PMID: 38893278 PMC: 11172073. DOI: 10.3390/cancers16112160.

The mysterious association between adiponectin and endometriosis.

Zhao Y, Ren Y, Li B, Wei C, Yu B Front Pharmacol. 2024; 15:1396616.

PMID: 38813109 PMC: 11133721. DOI: 10.3389/fphar.2024.1396616.

Focusing on the role of protein kinase mTOR in endometrial physiology and pathology: insights for therapeutic interventions.

Wang B, Gao M, Yao Y, Li H, Zhang X Mol Biol Rep. 2024; 51(1):359.

PMID: 38400863 DOI: 10.1007/s11033-023-08937-w.

Diminished Ovarian Reserve in Endometriosis: Insights from In Vitro, In Vivo, and Human Studies-A Systematic Review.

Tan Z, Gong X, Wang C, Zhang T, Huang J Int J Mol Sci. 2023; 24(21).

PMID: 37958954 PMC: 10647261. DOI: 10.3390/ijms242115967.

References

Johnson N, Hummelshoj L . Consensus on current management of endometriosis. Hum Reprod. 2013; 28(6):1552-68. DOI: 10.1093/humrep/det050. View

Meresman G, Bilotas M, Abello V, Buquet R, Tesone M, Sueldo C . Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis. Fertil Steril. 2005; 84(2):459-63. DOI: 10.1016/j.fertnstert.2005.01.137. View

Wang Y, Lin M, Weng H, Wang X, Yang L, Liu F . ENMD-1068, a protease-activated receptor 2 antagonist, inhibits the development of endometriosis in a mouse model. Am J Obstet Gynecol. 2014; 210(6):531.e1-8. DOI: 10.1016/j.ajog.2014.01.040. View

Baselga J, Campone M, Piccart M, Burris 3rd H, Rugo H, Sahmoud T . Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2011; 366(6):520-9. PMC: 5705195. DOI: 10.1056/NEJMoa1109653. View

Donnez J, Smoes P, Gillerot S, Nisolle M . Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod. 1998; 13(6):1686-90. DOI: 10.1093/humrep/13.6.1686. View

Yildiz C, Kacan T, Bozoklu Akkar O, Karakus S, Seker M, Kacan S . Effect of imatinib on growth of experimental endometriosis in rats. Eur J Obstet Gynecol Reprod Biol. 2016; 197:159-63. DOI: 10.1016/j.ejogrb.2015.12.013. View

Harada T, Kaponis A, Iwabe T, Taniguchi F, Makrydimas G, Sofikitis N . Apoptosis in human endometrium and endometriosis. Hum Reprod Update. 2004; 10(1):29-38. DOI: 10.1093/humupd/dmh007. View

Amsterdam L, Gentry W, Jobanputra S, Wolf M, Rubin S, Bulun S . Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril. 2005; 84(2):300-4. DOI: 10.1016/j.fertnstert.2005.02.018. View

McLaren J . Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update. 2000; 6(1):45-55. DOI: 10.1093/humupd/6.1.45. View

10.

Streuli I, de Ziegler D, Santulli P, Marcellin L, Borghese B, Batteux F . An update on the pharmacological management of endometriosis. Expert Opin Pharmacother. 2013; 14(3):291-305. DOI: 10.1517/14656566.2013.767334. View

11.

Gibran L, Maranhao R, Abrao M, Baracat E, Podgaec S . Could statins constitute a novel treatment for endometriosis? Systematic review of the literature. Eur J Obstet Gynecol Reprod Biol. 2014; 179:153-8. DOI: 10.1016/j.ejogrb.2014.05.028. View

12.

Leavy O . Reproductive immunology: Evading immunosurveillance in endometriosis. Nat Rev Immunol. 2015; 15(12):729. DOI: 10.1038/nri3942. View

13.

Remmele W, Stegner H . [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987; 8(3):138-40. View

14.

Johnson N, Farquhar C, Crossley S, Yu Y, van Peperstraten A, Sprecher M . A double-blind randomised controlled trial of laparoscopic uterine nerve ablation for women with chronic pelvic pain. BJOG. 2004; 111(9):950-9. DOI: 10.1111/j.1471-0528.2004.00233.x. View

15.

Keenan J, MASSEY P, Chen T, Caudle M, Bukovsky A . Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril. 1999; 72(1):135-41. DOI: 10.1016/s0015-0282(99)00157-0. View

16.

Suo G, Sadarangani A, Tang W, Cowan B, Wang J . Telomerase expression abrogates rapamycin-induced irreversible growth arrest of uterine fibroid smooth muscle cells. Reprod Sci. 2014; 21(9):1161-70. PMC: 4212341. DOI: 10.1177/1933719114532839. View

17.

Ellard S, Clemons M, Gelmon K, Norris B, Kennecke H, Chia S . Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009; 27(27):4536-41. DOI: 10.1200/JCO.2008.21.3033. View

18.

Thangavelu A, Hewitt M, Quinton N, Duffy S . Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study. Gynecol Oncol. 2013; 131(3):613-8. DOI: 10.1016/j.ygyno.2013.09.023. View

19.

Yagyu T, Tsuji Y, Haruta S, Kitanaka T, Yamada Y, Kawaguchi R . Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis. Int J Gynecol Cancer. 2006; 16(4):1545-51. DOI: 10.1111/j.1525-1438.2006.00625.x. View

20.

Cinar O, Seval Y, Uz Y, Cakmak H, Ulukus M, Kayisli U . Differential regulation of Akt phosphorylation in endometriosis. Reprod Biomed Online. 2009; 19(6):864-71. DOI: 10.1016/j.rbmo.2009.10.001. View